Immunology company Zura Bio Limited (Nasdaq: ZURA) announced on Monday that it has initiated TibuSURE, a Phase 2 global study to evaluate tibulizumab for systemic sclerosis (SSc) in adults. The trial is the first to explore dual inhibition of BAFF and IL-17 pathways in this rare autoimmune disease.
TibuSURE will assess the safety, tolerability and efficacy of tibulizumab in approximately 80 participants with early diffuse cutaneous systemic sclerosis over a 24-week period, followed by a 28-week open-label extension. Key endpoints include the modified Rodnan Skin Score, lung function measures and patient-reported outcomes.
Systemic sclerosis affects 300,000 individuals globally and has limited treatment options. Tibulizumab, a bispecific antibody targeting IL-17A and BAFF, aims to address the disease's multisystem impact.
Zura Bio is also advancing tibulizumab for hidradenitis suppurativa, with Phase 2 trials planned for 2025. The company's portfolio includes additional assets, crebankitug and torudokimab, targeting autoimmune and inflammatory conditions with high unmet needs.
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
ANGLE plc reports successful dual CTC-DNA and ctDNA analysis using Illumina platform
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Vast Therapeutics receives USD2m grant from National Institutes of Health
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
bioAffinity Technologies declares successful beta launch of CyPath Lung in Texas